Strategy Analytics: China’s Dual Credit Policy – Winners and Losers in 2020
Variation Across the 2020 Dual Credit Results for Individual OEMs BOSTON–(BUSINESS WIRE)–China’s Dual Credit policy…
Variation Across the 2020 Dual Credit Results for Individual OEMs BOSTON–(BUSINESS WIRE)–China’s Dual Credit policy…
The network upgrades in Guernsey, Jersey, London and Paris ensure Sure’s future growth Channel Islands,…
Internet City, Dubai–(Newsfile Corp. – February 16, 2022) – LBank Exchange, a global digital asset…
Vancouver, British Columbia–(Newsfile Corp. – February 16, 2022) – NetCents Technology Inc. (CSE: NC) (FSE:…
Multivendor software-driven architecture showcases route to enhanced mobile business opportunities and critical user experiences SUNNYVALE,…
Marks Tofane Global’s sixth acquisition in four years and accelerates iBASIS’ Internet of Things (IoT)…
London–UK, Quadient a leader in helping businesses create meaningful customer connections through digital and physical…
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a…
MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company…
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY) the world’s first…
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the…
REDWOOD CITY, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the…
Asserts Certara’s leadership in advancing the development and approval of new drugs for patients PRINCETON,…
TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:…
HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has…
SEATTLE, Feb. 15, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial…
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics…
TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:…
CALGARY, Alberta, Feb. 15, 2022 (GLOBE NEWSWIRE) — Carbeeza Inc. (the “Company”; TSX.V: AUTO) is…